The collection of last week's news with bio and health-tech
Eliem Therapeutics Raises $60M Series B Financing
Eliem Therapeutics., a Seattle, WA- and Cambridge, England, UK-based clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders, closed a $60m Series B financing.
The round was led by Intermediate Capital Group (ICG) and RA Capital Management with participation from Access Biotechnology, Samlyn Capital, Acorn Bioventures and LifeArc.
The company intends to use the funds to advance its two lead clinical-stage product candidates, ETX-810 and ETX-155, through topline data across four different indications in patients with chronic pain, depressive disorders, and epilepsy, as well as to advance its two preclinical-stage programs to selection of clinical development candidates.
Led by Bob Azelby, President and Chief Executive Officer, Eliem Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems.
Eliem Therapeutics Raises $60M Series B Financing
Eliem Therapeutics., a Seattle, WA- and Cambridge, England, UK-based clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders, closed a $60m Series B financing
ExeVir Closes US$50M Series A Financing
ExeVir, a Ghent, Belgium-based company developing single domain antibody therapies providing broad protection against viral infections, closed its Series A financing raising a total of US$50m.
The financing, announced in March 2021, was led by Fund+ with participation from VIB, UCB Ventures, SFPI-FPIM, V-Bio Ventures and new investors SRIW, Noshaq, Vives IUF, SambrInvest, as well as several Belgian family offices.The company is using the funds to commence the global phase 1b/2 clinical trial of lead compound XVR011 and develop a VHH72-Fc sub-cutaneous formulation for Covid-19 in parallel and accelerate development of its pipeline beyond Covid-19 in infectious diseases.
Led by Torsten Mummenbrauer, CEO, ExeVir Bio leverages the VHH technology platform to generate antiviral therapies providing broad protection against viral infections, including coronaviruses. It is a spin out from VIB, the world class Belgium-based life sciences research institute, based on the work of Professor Drs Xavier Saelens and Nico Callewaert from VIB in collaboration.
ExeVir Closes US$50M Series A Financing | FinSMEs
ExeVir, a Ghent, Belgium-based company developing single domain antibody therapies providing broad protection against viral infections, closed its Series A financing raising a total of US$50m
Arch Oncology Raises $105M in Series C Financing
Arch Oncology, Inc., a Brisbane, Calif. and St. Louis, MO-based clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 biologic therapies, closed a $105m Series C financing.
The round, announced in April 2021, was co-led by Eventide Asset Management, Cowen Healthcare Investments and current investor 3×5 Partners, who were joined by new investors Adage Capital Management, Point72 Asset Management, Avego Healthcare Capital, FMB Research and Broadfin Holdings. Existing investors include Roche Venture Fund, RiverVest Venture Partners, and Lightchain. The company is using the funds to expand its development efforts.
Led by Laurence Blumberg, M.D., President and Chief Executive Officer, Arch Oncology is a clinical-stage immuno-oncology company focused on the discovery and development of biologic therapies for the treatment of patients with solid tumors and hematologic malignancies.
Arch Oncology Raises $105M in Series C Financing | FinSMEs
Arch Oncology, Inc., a Brisbane, Calif. and St. Louis, MO-based clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 biologic therapies, closed a $105m Series C financing
Sera Prognostics Completes $100M Series E Financing
Sera Prognostics, Inc., a Salt Lake City, UT-based pregnancy company, closed a $100m Series E financing.
Backers included Vivo Capital, aMoon Fund, Parian Global, and others, led by existing investors Anthem, Inc., and Blue Ox Healthcare Partners.
The company intends to use the funds to commercialize its PreTRM® testing, accelerate the development of its pipeline of biomarker tests to predict other major conditions of pregnancy, and develop testing capacity for over 3 million annual pregnancies that are candidates for its PreTRM® Test in the United States.
Led by Gregory C. Critchfield, M.D., M.S., Chairman and CEO, Sera Prognostics focuses on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients.
Its first commercial product, the PreTRM® Test, is a clinically validated, commercially available blood-based biomarker test to accurately predict the risk of preterm birth. In addition to the PreTRM® Test, Sera is developing a pipeline of novel blood-based biomarker tests for a number of major pregnancy-related conditions beyond preterm birth.
Sera Prognostics Completes $100M Series E Financing
Sera Prognostics, Inc., a Salt Lake City, UT-based pregnancy company, closed a $100m Series E financing
HiberCell Raises $67.4M in Series B Financing; Secures $30M Debt Facility from Hercules Capital
HiberCell, a NYC-based biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, completed a Series B financing round for gross proceeds of $67.4m.
Concurrent to this financing, the company closed on a $30m debt facility with Hercules Capital, Inc. (NYSE: HTGC).
The Series B round included new investors Huizenga Capital Management, Monashee Investment Management, funds managed by Tekla Capital Management LLC, Hercules Capital, Mount Sinai Innovation Partners and other undisclosed investors.
The company will use the proceeds of the Series B financing and debt facility to support the clinical development of novel therapeutics targeting stress biology and innate immunity to address the role these play in prevention of cancer recurrence and metastasis.
Led by Alan Rigby, Ph.D., Co-Founder and Chief Executive Officer, HiberCell is biotechnology company dedicated to developing therapeutic molecules that overcome foundational scientific barriers that prevent patients from living longer, cancer-free lives. The company views cancer as a chronic disease and is working to develop novel therapies that address relapse and metastasis.
HiberCell Raises $67.4M in Series B; Secures $30M Debt Facility
HiberCell, a NYC-based biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, completed a Series B financing round for gross proceeds of $67.4m and closed on a $30m debt facility with Hercules Capital
Appia Bio Raises $52M in Series A Financing
Appia Bio, Inc., a Los Angeles, CA-based early stage biotechnology company developing engineered allogeneic cell therapies from hematopoietic stem cells (HSCs) for cancer patients, launched from stealth with $52m in Series A financing.
The round was led by 8VC with participation from Two Sigma Ventures, and seed investors Sherpa Healthcare Partners and Freeflow Ventures.
Proceeds will be used to progress stem cell derived CAR-engineered invariant natural killer T cells (CAR-iNKT) to the clinic in hematological and solid tumor indications
Led by JJ Kang, PhD, co-founder and chief executive officer, Appia Bio is focused on discovering and developing off-the-shelf allogeneic cell therapies across a broad array of cancer indications, utilizing a scalable technology platform with the goal to increase access for patients. With its ACUA technology platform, the company leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cells from HSCs.
Appia Bio Raises $52M in Series A Financing | FinSMEs
Appia Bio, Inc., a Los Angeles, CA-based early stage biotechnology company developing engineered allogeneic cell therapies from hematopoietic stem cells (HSCs) for cancer patients, launched from stealth with $52m in Series A financing.
Wheel Raises $50M in Series B Funding
Wheel, an Austin, Texas-based health tech company, raised $50m in Series B funding.
The round was led by Lightspeed Ventures with participation from CRV, Silverton Partners, Tusk Venture Partners, J.P. Morgan, and Future Shape.
The company, which has raised $66m in total to date, intends to use the capital to invest in its technology and clinician networks.
Led by CEO and cofounder Michelle Davey, Wheel provides a white label platform for companies and clinicians to build virtual care services under their brand. The technology connects patients with clinicians across more than a dozen attributes, ensuring patients are matched with the best clinician for their care needs. The company serves companies across a wide variety of industries, including publicly-traded digital health companies, tech companies, retailers, labs, and medical device companies.
Wheel Raises $50M in Series B Funding
Wheel, a Austin, Texas-based health tech company, raised $50m in Series B funding. The round was led by Lightspeed Ventures
Cynerio Raises $30M in Series B Funding
Cynerio, a NYC-based provider of Healthcare IoT cybersecurity and asset management solutions, secured $30m in Series B funding.
The round was led by Alive Israel HealthTech Fund, with participation from existing investors Accelmed, RDC, MTIP, CBG London investment company owned by Vincent Tchenguiz, and UAE based investment group.
The company will use the funding to:
expand its channel program, accelerate technological development, enhance support to existing customers, and reinforce its position in North America.
Led by Leon Lerman, CEO and co-founder, Cynerio provides a Healthcare IoT cybersecurity platform that covers every threat vector on every connected device. The clinically-intelligent platform automates asset discovery and risk reduction, and provides healthcare teams with the ability to not just identify more problems on their network, but to actually solve them and secure their organization to ensure patient safety, data integrity and operational continuity.
Cynerio Raises $30M in Series B Funding | FinSMEs
Cynerio, a NYC-based provider of Healthcare IoT cybersecurity and asset management solutions, secured $30m in Series B funding
SymphonyRM Raises $25M In Series B Funding
SymphonyRM, a Palo Alto, CA-based provider of AI powered patient engagement solutions for health systems, raised $25m in Series B funding.
The round was led by new investment partner TT Capital Partners (TTCP) with continued investment from Adams Street Partners.
The company intends to use the funds to accelerate sales and marketing efforts and to increase their reach and presence in the payer segment.
Led by Michael Linnert, CEO, SymphonyRM provides health systems with a platform to acquire, engage, and retain patients. By generating data-driven, prioritized next best actions for every consumer, prospect, and provider in a health system, the solution enables organizations to anticipate member needs and use proactive outreach to build deeper customer relationships and drive outcomes while increasing revenue.
SymphonyRM Raises $25M In Series B Funding | FinSMEs
SymphonyRM, a Palo Alto, CA-based provider of AI powered patient engagement solutions for health systems, raised $25m in Series B funding
RenBio Raises $24M in Series A Funding
RenBio, a New York-based preclinical biotechnology company, raised $24m Series A funding.
The round was led by Taiwan-based Ruentex Group.
The company intends to use the funds to complete IND-enabling preclinical studies and initiate a Phase 1/2 clinical trial of RB-100 in 2021 and continue the development of its proprietary, DNA-based MYO (Make Your Own) Technology™ antibody delivery platform, with the goal of advancing a lead candidate into the clinic within two years.
Co-founded by HIV expert, David D. Ho, M.D., founding scientific director of the Aaron Diamond AIDS Research Center and Professor of Medicine at Columbia University Vagelos College of Physicians and Surgeons, and Yaoxing Huang, Ph.D., Associate Professor of Medical Sciences at Columbia University Vagelos College of Physicians and Surgeons, and led by Neal N. Padte, Ph.D., Chief Operating Officer and Chief Development Officer, and Rachel A. Liberatore, Ph.D., Director of Research and Development, RenBio is a preclinical biotechnology company developing novel antiviral antibody therapeutics and a next-generation antibody delivery platform. The company’s lead compound, RB-100, is a SARS-CoV-2 bispecific antibody in-licensed from Columbia University, that, in preclinical studies, has demonstrated robust antiviral activity against emerging and evolving SARS-CoV-2 variants.
RenBio Raises $24M in Series A Funding | FinSMEs
RenBio, a New York-based preclinical biotechnology company, raised $24m Series A funding
Giiant Pharma Closes US$11M Seed Funding
Giiant Pharma Inc., a Montreal, Canada based preclinical-stage biotech company, raised US$11M in seed funding.
The round was led by Amplitude Ventures and Genesys Capital, with participation from Fonds de solidarité FTQ, AmorChem II Fund, Theodorus Investment Funds, Anges Québec, and other angel investors.
The company intends to use the funds to initiate its IND-enabling preclinical program with its lead candidate, GT-2108, for the treatment of moderate-to-severe ulcerative colitis.
Led by Maxime Ranger, CEO, Dr. Elizabeth Kwong, Chief Development Officer, and Patrick Colin, Chief Clinical Officer, Giiant is a preclinical-stage biotech company that, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology. Its lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrugs, with improved drug tolerability and enhanced therapeutic effect.
Giiant Pharma Closes US$11M Seed Funding | FinSMEs
Giiant Pharma Inc., a Montreal, Canada based preclinical-stage biotech company, raised US$11M in seed funding
Memora Health Closes $10.5M Funding Round
Memora Health, a San Francisco CA-based technology company which is building an intelligent platform for virtual care delivery, patient navigation and management, closed a $10.5M financing round.
The round was led by Andreessen Horowitz with participation from AlleyCorp, Martin Ventures, Kevin Durant and Rich Kleiman’s Thirty Five Ventures, Sachin Jain, Operator Partners, Edward Elmhurst Health, B Capital, and Aaron Szekel. As part of the financing, Andreessen Horowitz General Partner Vineeta Agarwala will join the Memora Health board.
The company intend to use the funds to expand operations and business reach.
Led by CEO and co-founder Manav Sevak, Memora Health is a technology company building an intelligent platform for virtual care delivery, patient navigation, and complex care management.
Memora Health Closes $10.5M Funding Round | FinSMEs
Memora Health, a San Francisco CA-based technology company which is building an intelligent platform for virtual care delivery, patient navigation and management, closed a $10.5M financing round
Atonarp Raises $50M in Series D Financing
Atonarp, a manufacturer of molecular sensing and diagnostics products for the healthcare, pharma, and semiconductor industries with operations in Japan, India, and the United States, raised $50m in Series D financing.
The round was led by WRVI Capital with participation from Furukawa Electric, Japan Post Investment, Boscolo Intervest, ATI Korea, and Banner Industries. In conjunction with the funding, WRVI Capital Founding Partner Michael Marks joined Atonarp’s Board.
The company, which has raised $111M in funding to date, intends to use the funds to expand its operations and expedite the development and commercialization of its molecular diagnostics products.
Founded in 2010 by president and CEO, CTO, and founder Prakash Murthy, and also led by newly appointed COO Shaun Holt, Atonarp is a molecular diagnostics company innovating how sensing and diagnostics devices are applied to generate real-time actionable data and achieve improved outcomes in healthcare and industrial semiconductor processes.
Atonarp Raises $50M in Series D Financing | FinSMEs
Atonarp, a manufacturer of molecular sensing and diagnostics products for the healthcare, pharma, and semiconductor industries, raised $50m in Series D financing
UltraSight Raises $13M in Series B Funding
UltraSight (formerly OnSight Medical), a Tel Aviv, Israel-based digital health company focused on cardiac imaging, raised $13M in Series B funding.
The round was led by Yozma Group Korea, Atain Specialty Insurance Company and the Weizmann Institute of Science.
The company intends to use the funds to advance U.S. clinical programs for its real time, AI guidance in a variety of care settings.
Led by Davidi Vortman, CEO, UltraSight provides an AI platform for ultrasound devices to conduct sonography at the point of care. Point of care ultrasound allows medical professionals to diagnose patients wherever they are including clinics, community hospitals, ambulances and remote settings.
